China
Africa
Explore chapters and articles related to this topic
Bladder Cancer
Published in Dongyou Liu, Tumors and Cancers, 2017
Tumors affecting the urinary tract consist of eight categories: (1) urothelial tumors (infiltrating urothelial carcinoma [with squamous differentiation, with glandular differentiation, with trophoblastic differentiation, nested, microcystic, micropapillary, lymphoepithelioma-like, lymphoma-like, plasmacytoid, sarcomatoid, giant cell, and undifferentiated] and noninvasive urothelial neoplasias [urothelial carcinoma in situ, noninvasive papillary urothelial carcinoma—high grade, noninvasive papillary urothelial carcinoma—low grade, noninvasive papillary urothelial neoplasm of low malignant potential, urothelial papilloma, and inverted urothelial papilloma]), (2) squamous neoplasms (squamous cell carcinoma [SCC], verrucous carcinoma, and squamous cell papilloma), (3) glandular neoplasms (adenocarcinoma [enteric, mucinous, signet ring cell, and clear cell] and villous adenoma), (4) neuroendocrine tumors (small cell carcinoma, carcinoid, and paraganglioma), (5) melanocytic tumors (malignant melanoma and nevus), (6) mesenchymal tumors (rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, osteosarcoma, malignant fibrous histiocytoma, leiomyoma, and hemangioma), (7) hematopoietic and lymphoid tumors (lymphoma and plasmacytoma), and (8) miscellaneous tumors (carcinoma of Skene, Cowper, and Littre glands; metastatic tumors and tumors extending from other organs) [1].
Do repeated transurethral procedures under general anesthesia influence mortality in patients with non-invasive urothelial bladder cancer? A Danish national cohort study
Published in Scandinavian Journal of Urology, 2020
Marie Schmidt Erikson, Astrid Christine Petersen, Klaus Kaae Andersen, Frederik Krogsdal Jacobsen, Karin Mogensen, Gregers Gautier Hermann
All patients diagnosed with primary non-invasive urothelial carcinoma during the inclusion period were identified from the DBCC. To minimize under staging, the primary diagnosis was defined as the worst diagnosis within a period of 6 months from the patient’s first evaluation. Primary urothelial papilloma (n = 88) and urothelial dysplasia (n = 55) were excluded. Papillary urothelial neoplasms of low malignant potential (n = 985) were categorized as TaLG. Papillary tumors with concomitant CIS (n = 236) were categorized as TaHG. In total, 10,197 patients with primary TaLG, TaHG, or CIS were included at the time of diagnosis for statistical analysis. Variables known to be associated with risk of death were included at baseline: civil status (CPR), income and educational level (Statistics Denmark) [19] and CCI (calculated from DNPR data).
National incidence and survival of patients with non-invasive papillary urothelial carcinoma: a Danish population study
Published in Scandinavian Journal of Urology, 2018
Marie Schmidt Erikson, Astrid Christine Petersen, Klaus Kaae Andersen, Anne Helms Andreasen, Søren Friis, Karin Mogensen, Gregers Gautier Hermann
Data on all Danish residents with primary urothelial neoplasia in the bladder from 1 January 2000 to 31 December 2010 were included and followed until 1 January 2016. Patients with urothelial papilloma (n = 88) or primary low grade urothelial dysplasia (n = 55) were excluded. The population were divided into sub-groups of Ta LG, Ta HG, CIS and invasive carcinomas (stage T1–T4). Patients with papillary urothelial neoplasm of low malignant potential (PUNLMP) (n = 985) were categorized as Ta LG. Patients with Ta LG and concomitant CIS (n = 111) or Ta HG and CIS (n = 125) were categorized as Ta HG. In total, 17,941 patients diagnosed with primary urothelial neoplasia with a total observation time of 133,920 years (Table 2) were included for statistical analysis.